Alirocumab for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Alirocumab for Health & Longevity

Created on 06/30/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

An injectable antibody that sharply lowers harmful cholesterol when diet and statins fall short, especially for inherited high cholesterol or existing heart disease. In high-risk people it lowers heart attacks, strokes, and heart-related death. Main limits are cost, regular self-injection, and little long-term data in younger, lower-risk people. (Full Review)

Protocol

Starting Dose
75 mg every 2 weeks
Subcutaneous self-injection; timing flexible
Up-Titration
150 mg every 2 weeks
If more LDL lowering needed; 300 mg monthly option exists
Background Therapy
Add to maximally tolerated statin
Often with ezetimibe; not a first-line replacement
Time to effect
LDL Lowering Begins
1–2 weeks
Measurable reduction in LDL cholesterol
Near-Maximal LDL Effect
4–8 weeks
Recheck LDL to confirm response
Cardiovascular Benefit
Months to years
Accrues over sustained use, not immediately

Benefits

Contraindications
  • History of serious hypersensitivity (severe allergic reaction or vasculitis) to alirocumab
  • Pregnancy and breastfeeding
  • Homozygous familial hypercholesterolemia with no residual LDL-receptor function
    •
Key Interactions
  • Statins (atorvastatin, rosuvastatin) and ezetimibe
  • Additive LDL-lowering supplements (plant sterols/stanols, soluble fiber, red yeast rice, berberine)
  • Other PCSK9-directed therapies (inclisiran)
    •

Risk & Side Effects

  • High: Injection-site reactions
    •
  • Medium: Hypersensitivity and allergic reactions; flu-like and upper-respiratory symptoms
    •
  • Low: Neurocognitive concerns; new-onset or worsening diabetes
    •
  • Speculative: Unknown very-long-term effects of sustained very low LDL
    •

Monitoring

Marker Target Why
LDL cholesterol (LDL-C) <70 mg/dL high-risk; many target <55 mg/dL Primary efficacy target
Apolipoprotein B (apoB) <60–80 mg/dL (lower for high risk) Counts atherogenic particles directly
Lipoprotein(a) [Lp(a)] <75 nmol/L (<30 mg/dL) Inherited residual-risk particle
Non-HDL cholesterol <100 mg/dL (lower for high risk) Captures all atherogenic lipids if apoB unavailable
Fasting glucose / HbA1c HbA1c <5.7% Screen the theoretical diabetes question

Cadence: Lipid recheck ~4–8 weeks after initiation or dose change, then every 6–12 months once stable.

Qualitative Assessment

  • Subjective tolerability — presence, severity, and trend of injection-site reactions over the first several doses
  • Any allergic-type symptoms (rash, swelling, breathing difficulty) prompting medical review
  • Adherence and confidence with the self-injection routine
  • General energy and well-being, to distinguish drug effects from unrelated symptoms
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.